Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SCYNEXISSCYX -1.15%40 Net Cash per Share is $4.63 as of Jun. 2026. GuruFocus rates SCYX with a GF Score™ of 40/100 and a GF Value™ of $17.51 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 252 Drug Manufacturers companies, SCYNEXIS ranks better than 93.65% on this metric.
SCYNEXIS (NAS:SCYX) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
SCYNEXIS Net Cash per Share Related Terms
SCYNEXIS Net Cash per Share Historical Data
* Premium members only.
The historical data trend for SCYNEXIS's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCYX vs TLPH, IXHL, CPHI: Net Cash per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SCYNEXIS Price-to-Net-Cash vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where SCYNEXIS's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
SCYNEXIS's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCYNEXIS (SCYX) has a Net Cash per Share of $4.63 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on SCYNEXIS and its competitors. According to the industry distribution chart, SCYNEXIS ranks #16 out of 252 companies in the Drug Manufacturers industry, placing it in the top 6.3%.
Is SCYNEXIS's Net Cash per Share too high?
SCYNEXIS's current Net Cash per Share is $4.63. The Drug Manufacturers industry median Net Cash per Share is 8.62. SCYNEXIS's value of $4.63 is 46.3% below this industry median. Based on the distribution chart, SCYNEXIS ranks #16 out of 252 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, SCYNEXIS has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SCYNEXIS's Net Cash per Share compare to TLPH and IXHL?
According to the Drug Manufacturers industry distribution chart, SCYNEXIS ranks #16 out of 252 companies for Net Cash per Share. This places SCYNEXIS in the top 6% of its industry — outperforming the majority of peers. The industry median Net Cash per Share is 8.62. SCYNEXIS's value of $4.63 is 46.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Drug Manufacturers company?
The median Net Cash per Share among Drug Manufacturers companies is 8.62, based on 252 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SCYNEXIS's current Net Cash per Share of $4.63 is 46.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on SCYNEXIS and its competitors. For the Drug Manufacturers industry, the median Net Cash per Share is 8.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SCYNEXIS's current Net Cash per Share is $4.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SCYNEXIS stock overvalued right now?
Based on GuruFocus' analysis, SCYNEXIS (SCYX) is currently considered Possible Value Trap. The stock's GF Value™ is $17.51, compared to a current price of $5.13 — trading 70.7% below its estimated fair value. The current Net Cash per Share is $4.63 and 46.3% below the Drug Manufacturers industry median of 8.62. SCYNEXIS's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For SCYNEXIS (SCYX), the current Net Cash per Share is $4.63 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SCYNEXIS (SCYX) Overvalued in 2026?
Based on GuruFocus' analysis, SCYNEXIS stock appears to be undervalued.
The current stock price of $5.13 is trading 70.7% below its estimated GF Value™ of $17.51.
GuruFocus considers SCYNEXIS to be Possible Value Trap.
Key valuation signals for SCYX:
Net Cash per Share: $4.63
GF Value™: $17.51 vs. price of $5.13 (70.7% below fair value)
Industry Position: 46.3% below the Drug Manufacturers median (#16 of 252)
No single metric tells the full story. See the SCYX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
40GF Score
Get the complete analysis for SCYX
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCYX has been successfully added to your 
